Related references
Note: Only part of the references are listed.Subacute liver failure induced by adalimumab
S. Hagel et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis
Jeremy Sokolove et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Autoimmune Hepatitis Induced by Infliximab in a Patient with Crohn's Disease with no Relapse After Switching to Adalimumab
Marilia Cravo et al.
BIODRUGS (2010)
Infliximab-induced acute hepatitis during Crohn's disease therapy: Absence of cross-toxicity with adalimumab
A. Haennig et al.
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE (2010)
Infliximab-related hepatitis: discussion of a case and review of the literature
Stefano Mancini et al.
INTERNAL AND EMERGENCY MEDICINE (2010)
A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease
W. Miehsler et al.
JOURNAL OF CROHNS & COLITIS (2010)
Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept
K. M. Carlsen et al.
CLINICAL RHEUMATOLOGY (2009)
Serious liver disease induced by infliximab
Gabriel J. Tobon et al.
CLINICAL RHEUMATOLOGY (2007)
Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients:: need for primary prophylaxis
M Esteve et al.
GUT (2004)
Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate
P Ostuni et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines
RAJ Ransford et al.
GUT (2002)
Share Paper
